In a welcome move, Axsome Therapeutics saw its Relative Strength Rating rise from 69 to 76 on Wednesday.
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their largest climbs. See if Axsome Therapeutics can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Axsome Therapeutics is not currently near a potential buy zone. See if the stock goes on to build a sound pattern that could spark a new run.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 81%.
The company holds the No. 104 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
